Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties

Nabiel Mohamed, David MeyerDivision of Ophthalmology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaBackground: Several studies have confirmed the ability of cannabinoids to reduce intraocular pressure. Experimental data recently demonstrated unequivocal...

Full description

Bibliographic Details
Main Authors: Mohamed N, Meyer D
Format: Article
Language:English
Published: Dove Medical Press 2013-01-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/intraocular-pressure-lowering-effect-of-oral-paracetamol-and-its-in-vi-a12098
_version_ 1819015632197255168
author Mohamed N
Meyer D
author_facet Mohamed N
Meyer D
author_sort Mohamed N
collection DOAJ
description Nabiel Mohamed, David MeyerDivision of Ophthalmology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaBackground: Several studies have confirmed the ability of cannabinoids to reduce intraocular pressure. Experimental data recently demonstrated unequivocally that the analgesic effect of paracetamol is due to its indirect action on cannabinoid receptors. The question then arises as to whether paracetamol can reduce intraocular pressure via its effect on intraocular cannabinoid receptors.Methods: A 2-week, prospective, randomized, controlled, single-center, parallel-group pilot study was carried out to determine the efficacy and safety of paracetamol 1 g orally administered every 6 hours in adult patients with primary or secondary open angle glaucoma as compared with topical levobunolol 0.5% twice a day. Patient well-being was closely monitored throughout the study and focused on hepatic safety in accordance with Drug-Induced Liver Injury Network criteria. The in vitro diffusion kinetics of acetaminophen in a phosphate-buffered solution in rabbit and human corneas was also investigated, with the view to a topical application.Results: Eighteen adult patients were enrolled in the study, with nine in the topical levobunolol group and nine in the oral paracetamol group. In the levobunolol group, the mean reduction in intraocular pressure at day 7 was 7.5 mmHg (P < 0.008) and at day 14 was 9.1 mmHg (P < 0.005), from a mean baseline intraocular pressure of 29.6 mmHg. The corresponding figures for the paracetamol group were 8.8 mmHg (P < 0.0004) at day 7 and 6.5 mmHg (P < 0.004) at day 14, from a mean baseline intraocular pressure of 29.4 mmHg. Both study regimens were well tolerated. No serious treatment-related adverse events were reported in either of the treatment groups. Liver function tests, systolic/diastolic blood pressure, or heart rate remained unchanged in both groups during the 2 weeks of the study. In the laboratory study, paracetamol 1 mg/mL in phosphate-buffered solution (pH 7.4) showed acceptable flux rates. Steady-state levels were achieved within 12 hours, thus confirming that paracetamol penetrates the cornea well.Conclusion: Paracetamol 1 g taken orally every 6 hours reduced open angle glaucoma and/or angle recession glaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergic receptor antagonist.Keywords: acetaminophen, paracetamol, glaucoma, intraocular pressure, cannabinoids
first_indexed 2024-12-21T02:34:49Z
format Article
id doaj.art-07fd46e344fa4951aa635e3af8c5c497
institution Directory Open Access Journal
issn 1177-5467
1177-5483
language English
last_indexed 2024-12-21T02:34:49Z
publishDate 2013-01-01
publisher Dove Medical Press
record_format Article
series Clinical Ophthalmology
spelling doaj.art-07fd46e344fa4951aa635e3af8c5c4972022-12-21T19:18:49ZengDove Medical PressClinical Ophthalmology1177-54671177-54832013-01-012013default219227Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration propertiesMohamed NMeyer DNabiel Mohamed, David MeyerDivision of Ophthalmology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaBackground: Several studies have confirmed the ability of cannabinoids to reduce intraocular pressure. Experimental data recently demonstrated unequivocally that the analgesic effect of paracetamol is due to its indirect action on cannabinoid receptors. The question then arises as to whether paracetamol can reduce intraocular pressure via its effect on intraocular cannabinoid receptors.Methods: A 2-week, prospective, randomized, controlled, single-center, parallel-group pilot study was carried out to determine the efficacy and safety of paracetamol 1 g orally administered every 6 hours in adult patients with primary or secondary open angle glaucoma as compared with topical levobunolol 0.5% twice a day. Patient well-being was closely monitored throughout the study and focused on hepatic safety in accordance with Drug-Induced Liver Injury Network criteria. The in vitro diffusion kinetics of acetaminophen in a phosphate-buffered solution in rabbit and human corneas was also investigated, with the view to a topical application.Results: Eighteen adult patients were enrolled in the study, with nine in the topical levobunolol group and nine in the oral paracetamol group. In the levobunolol group, the mean reduction in intraocular pressure at day 7 was 7.5 mmHg (P < 0.008) and at day 14 was 9.1 mmHg (P < 0.005), from a mean baseline intraocular pressure of 29.6 mmHg. The corresponding figures for the paracetamol group were 8.8 mmHg (P < 0.0004) at day 7 and 6.5 mmHg (P < 0.004) at day 14, from a mean baseline intraocular pressure of 29.4 mmHg. Both study regimens were well tolerated. No serious treatment-related adverse events were reported in either of the treatment groups. Liver function tests, systolic/diastolic blood pressure, or heart rate remained unchanged in both groups during the 2 weeks of the study. In the laboratory study, paracetamol 1 mg/mL in phosphate-buffered solution (pH 7.4) showed acceptable flux rates. Steady-state levels were achieved within 12 hours, thus confirming that paracetamol penetrates the cornea well.Conclusion: Paracetamol 1 g taken orally every 6 hours reduced open angle glaucoma and/or angle recession glaucoma in both groups of patients, in a way comparable with that achieved by a topical beta-adrenergic receptor antagonist.Keywords: acetaminophen, paracetamol, glaucoma, intraocular pressure, cannabinoidshttp://www.dovepress.com/intraocular-pressure-lowering-effect-of-oral-paracetamol-and-its-in-vi-a12098
spellingShingle Mohamed N
Meyer D
Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
Clinical Ophthalmology
title Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
title_full Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
title_fullStr Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
title_full_unstemmed Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
title_short Intraocular pressure-lowering effect of oral paracetamol and its in vitro corneal penetration properties
title_sort intraocular pressure lowering effect of oral paracetamol and its in vitro corneal penetration properties
url http://www.dovepress.com/intraocular-pressure-lowering-effect-of-oral-paracetamol-and-its-in-vi-a12098
work_keys_str_mv AT mohamedn intraocularpressureloweringeffectoforalparacetamolanditsinvitrocornealpenetrationproperties
AT meyerd intraocularpressureloweringeffectoforalparacetamolanditsinvitrocornealpenetrationproperties